BR9806866A - Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina. - Google Patents

Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina.

Info

Publication number
BR9806866A
BR9806866A BR9806866-0A BR9806866A BR9806866A BR 9806866 A BR9806866 A BR 9806866A BR 9806866 A BR9806866 A BR 9806866A BR 9806866 A BR9806866 A BR 9806866A
Authority
BR
Brazil
Prior art keywords
expression cassette
human
strain
animal
vaccine
Prior art date
Application number
BR9806866-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Stuart Coffin
David Seymout Latchman
Original Assignee
Neurovex Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovex Limited filed Critical Neurovex Limited
Publication of BR9806866A publication Critical patent/BR9806866A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR9806866-0A 1997-01-10 1998-01-12 Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina. BR9806866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700411.3A GB9700411D0 (en) 1997-01-10 1997-01-10 Eukaryotic gene expression cassette and uses thereof
PCT/GB1998/000074 WO1998030707A2 (en) 1997-01-10 1998-01-12 Eukaryotic gene expression cassette and uses thereof

Publications (1)

Publication Number Publication Date
BR9806866A true BR9806866A (pt) 2000-04-18

Family

ID=10805768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806866-0A BR9806866A (pt) 1997-01-10 1998-01-12 Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina.

Country Status (15)

Country Link
EP (2) EP1021553B1 (https=)
JP (1) JP2001508294A (https=)
KR (1) KR100507399B1 (https=)
CN (1) CN1231589C (https=)
AT (1) ATE267263T1 (https=)
AU (1) AU749064B2 (https=)
BR (1) BR9806866A (https=)
CA (1) CA2278326A1 (https=)
DE (1) DE69824027T2 (https=)
DK (1) DK1021553T3 (https=)
ES (1) ES2221980T3 (https=)
GB (1) GB9700411D0 (https=)
IL (2) IL130876A0 (https=)
PT (1) PT1021553E (https=)
WO (1) WO1998030707A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
GB9807865D0 (en) * 1998-04-09 1998-06-10 Univ London Herpes simplex virus latency associated transcript polypeptides
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
WO2000008193A2 (en) * 1998-07-31 2000-02-17 Cambridge University Technical Services Limited Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
US7514110B1 (en) 2000-09-21 2009-04-07 Basf Aktiengesellschaft Talaromyces xylanases
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
TWI328612B (en) 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
JP2006500062A (ja) * 2002-09-27 2006-01-05 パウダージェクト リサーチ リミテッド 遺伝子発現のための核酸構築物
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2005080581A2 (en) 2004-02-17 2005-09-01 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR20180136435A (ko) 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
AU2020284255A1 (en) * 2019-05-30 2022-01-06 Solid Biosciences Inc. Recombinant herpesvirales vector

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
DK0566554T3 (da) * 1992-03-13 2000-08-07 Monsanto Co Fremstilling af rekombinante proteiner ved anvendelse af herpesviruspromotorer og VP16-transaktivatorer

Also Published As

Publication number Publication date
KR20000070037A (ko) 2000-11-25
ATE267263T1 (de) 2004-06-15
AU749064B2 (en) 2002-06-20
EP1441033A3 (en) 2004-12-01
EP1021553B1 (en) 2004-05-19
ES2221980T3 (es) 2005-01-16
WO1998030707A2 (en) 1998-07-16
JP2001508294A (ja) 2001-06-26
DK1021553T3 (da) 2004-09-27
IL130876A (en) 2006-08-20
KR100507399B1 (ko) 2005-08-10
WO1998030707A3 (en) 1998-09-11
CN1250480A (zh) 2000-04-12
DE69824027D1 (de) 2004-06-24
GB9700411D0 (en) 1997-02-26
CN1231589C (zh) 2005-12-14
IL130876A0 (en) 2001-01-28
EP1441033A2 (en) 2004-07-28
AU5566998A (en) 1998-08-03
PT1021553E (pt) 2004-09-30
DE69824027T2 (de) 2004-10-28
CA2278326A1 (en) 1998-07-16
EP1021553A2 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
BR9806866A (pt) Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina.
Yao et al. Gene therapy in wound repair and regeneration
DK1214440T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
DE69637147D1 (de) Transportproteine und deren verwendungen
Huxley Mammalian artificial chromosomes: a new tool for gene therapy
PT832264E (pt) Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao.
CA2104396A1 (en) Viral particles having altered host range
CA2293612A1 (en) Regulation of transcription in mammalian cells and viral replication by a tetracyclin repressor
DE3471688D1 (en) Dna vectors and their use in recombinant dna technology
WO1996034969A3 (en) Gene therapy using replication competent targeted adenoviral vectors
DE69635173D1 (de) Rekombinante MVA Viren und deren Verwendung
DE69633236D1 (de) Gewebe-oder zellspezifische herpessimplex virus replikation
HUP9902310A2 (hu) Komplementer adenovírus-vektorrendszerek és sejtvonalak
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
ATE190354T1 (de) Kontrolle der genexpression durch ionisierende strahlung
NO303831B1 (no) Isolert DNA-sekvens, vektor, vertscelle, polypeptid og anvendelse in vitro av polypeptidet ved en fremgangsmÕte for transfeksjon av hematopoeseceller med eksogen DNA
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
CA2074188A1 (en) Vector with multiple tat activation response elements affecting gene expression
PT632129E (pt) Vectores recombinantes de virus sincicial para utilizacoes medicinais e de diagnostico e processos para a preparacao de vectores recombinantes de virus sincicial
AU3668389A (en) Exogenous gene expression vector containing chick beta-actin gene promoter
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
Lubon et al. Cell-specific activity of the human immunodeficiency virus enhancer repeat in vitro
BR9907759A (pt) ácido nucleico recombinante, vetor, vìrus recombinante defectivo, célula, utilização de uma construção, de um ácido nucleico, de um vìrus recombinante defectivo e de um vetor, composição, e, promotor quimérico
Stevens et al. Ionizing radiation, and other DNA damaging agents, can improve the integration of exogenous DNA into human and mammalian cells

Legal Events

Date Code Title Description
TE Change of address
TE Change of address
TC Change of name
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.